Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Item
http://www.wikidata.org/entity/Q36789883
Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015Treatment decisions in multiple sclerosis - insights from real-world observational studies.Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologicaThe sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.Long-term registries: Answering tough questions with big data?Observational studies and their utility for practice.
P2860

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Item
http://www.wikidata.org/entity/Q36789883
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Comparative efficacy of first- ...... ramer acetate in relapsing MS.
@en
type
label
Comparative efficacy of first- ...... ramer acetate in relapsing MS.
@en
prefLabel
Comparative efficacy of first- ...... ramer acetate in relapsing MS.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Comparative efficacy of first- ...... iramer acetate in relapsing MS
@en
P2093
P2860
P304
P31
P356
10.1212/CPJ.0000000000000227
P433
P478
P50
P577
P698
P932